Pfizer's ELREXFIO Succeeds In Phase 3 Trial For Multiple Myeloma
One daysingle sourceOne outlet reported this, in 2 reports over 1 day - no second voice in this corpus.
All 2 reports on Tue, 27 October 2026
What it is about
Who published it, and when
original reportfirst to report
rttnews.com
27 Oct, 12:32over 1 hour27 Oct, 12:37
How it spread - 2 original reports
Tue, 27 October 2026
2 reports- rttnews.com12:32first to report
On Tuesday, Pfizer's ELREXFIO (elranatamab) met the primary endpoint of progression-free survival (PFS) in the Phase 3 MagnetisMM-32 trial, reducing the risk of disease progression or death compared with standard treatment regimens.
- rttnews.com12:37
Pfizer (PFE) reported positive Phase 3 results for ELREXFIO in relapsed/refractory multiple myeloma, meeting its primary endpoint of progression-free survival and reducing the risk of disease progression or death.